Αρχειοθήκη ιστολογίου

Αναζήτηση αυτού του ιστολογίου

Τετάρτη 31 Μαρτίου 2021

A dynamic prognostic nomogram to predict the benefit from surgical treatment modality for patients with laryngeal squamous cell carcinoma

xlomafota13 shared this article with you from Inoreader

Abstract

Background

Although nonsurgical treatment strategy is increasingly adopted in patients with locoregionally advanced laryngeal squamous cell carcinoma (LSCC), survival disparities were reported between surgical treatment modality and organ preservation protocols, highlighting the great importance for accurate patients' selection.

Method

This secondary analysis used data from the Surveillance, Epidemiology, and End Results database between 2010 and 2015 with follow‐up data up to 2018. We developed and validated a dynamic prognostic nomogram for overall survival (OS) in 4237 patients with LSCC and subgroup of 2087 patients with locoregionally advanced laryngeal squamous cell carcinoma (LALSCC). Based on the total risk score derived from the dynamic nomogram, two well‐matched risk groups (i.e., low‐ and high‐risk) were created via X‐tile software and 1‐to‐1 propensity score matching (PSM); surgical treatment modality was compared with nonsurgical one in each risk group.

Results

A more accurate and convenient dynamic prognostic nomogram based on age, marital status, T category, N category, M category, tumor size, and tumor differentiation was developed and validated, of which the predictive performance was superior to that of TNM staging system. For high‐risk LALSCC selected by the dynamic nomogram, after 1‐to‐1 PSM, significantly improved OS was observed in patients with receiving surgical treatment compared to those receipt of nonsurgical management (restricted mean survival time at 36‐month: 26.6 vs 22.7, p < 0.001; restricted mean survival time at 60‐month: 36.7 vs 31.0, p = 0.003).

Conclusion

We establish and validate a more accurate and convenient dynamic prognostic nomogram for patients with LSCC, which may predict the benefit from surgical treatment modality for patients with high‐risk LALSCC.

View on the web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.